Growth hormone and glucose metabolism: the model of the GH-receptor antagonists - 16/02/08
A. J. Van der Lely
Voir les affiliationsGrowth hormone and glucose metabolism: the model of the GH-receptor antagonists |
Pegvisomant is a GH analogue that includes a single amino acid substitution at position 120 that generates the GHR antagonist. Additional changes include amino acid substitutions within binding site 1 and a further modification by the addition of polyethylene glycol moieties that increase the half-life and reduce the immunogenicity of the molecule. In acromegalics, pegvisomant is the most effective treatment for normalizing the IGF-I, and pegvisomant significantly improves insulin sensitivity in patients suffering from acromegaly. However, there are simply no data available that might support a role for pegvisomant treatment in disorders in which glucose metabolism is disturbed and in which reducing GH action would be theoretically beneficial.
Keywords:
Growth hormone
,
pegvisomant
,
IGF-1
,
glucose
Plan
© 2004 Elsevier Masson SAS. Tous droits réservés.
Vol 65 - N° 1
P. 81-83 - février 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.